Clinical Trial Update: Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial to evaluate safety and immunogenicity of a second-generation mRNA vaccine candidate targeting the H5 influenza hemagglutinin in healthy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Pandemic

Drugs mentioned

• H5 influenza mRNA vaccine candidate (second generation)

Snippet

Sponsor: Sanofi | Conditions: Pandemic Influenza Immunization, Healthy Volunteers | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING